POS0765 SERUM BASIC FIBROBLAST GROWTH FACTOR IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS

Background Patients with rheumatic diseases are at high risk for poor outcomes and gaps in care when severe fibrosis occur, as a result of tissue damage caused by chronic phase persistent inflammation. Only limited data also controversial results available on the predictors patients juvenile idiopathic arthritis (JIA) long-term methotrexate (MTX) treatment [1,2] Objectives To evaluate serum levels basic fibroblast growth factor (bFGF) children treated methotrexate. Methods 104 polyarthritis (50,96%) oligoarthritis (40,38%) variants JIA (mean age 13.3 yrs, 59,62 % female, mean onset 7.2 disease duration 5.06 yrs) were included this 4-years prospective study. In MTX 75.96 (vs. 24.04 not MTX, 16,35 prescribed but they didn’t receive any dose yet investigation day). Among 4.81 had less than 10 mg/m 2 /week, 32.69 10-12.5 31.73 12.6 - 15 6.73 over /week. bFGF determined ELISA kits (Elabscience, USA). Serum analyzed depending patients’ gender, age, onset, its variant, duration, activity, presence dose. Levels erythrocyte sedimentation rate (ESR), C-reactive protein (C-RP), circulating immune complex (CIC) antistreptolysin-O (ASL-O) Results We evaluated level (min: 4171.56 pg/ml; Me:7089.28 max: 18011.25 pg/ml). The average significantly increased from to 18 years versus up 3 (p = 0.009) 11–14 0.014). It was found higher an activity according JADAS-27 pattern low one 0.0005). Activity pattern, ESR, CIC ASL-O associated level. Mostly correlated (among: boys r=0.45, r=0.49, moderate r=0.58, r= 0.38, МТХ, 12,5-15mg/m2/week r=0.50 p ˂ 0.05), r=0.37, r=0.34, 10mg/m2/week r=0.96 ESR girls r=0.38, 0.05). Conclusion Children after old activity. corresponded Presence additional streptococcal infection impact formation JIA. References [1]Germolec DR, Shipkowski KA, Frawley RP, Evans E. Markers Inflammation. Mol Biol. 2018;1803:57-79. doi: 10.1007/978-1-4939-8549-4_5. PMID: 29882133. [2]Schuster R, Rockel JS, Kapoor M, Hinz B. inflammatory speech fibroblasts. Immunol Rev. 2021 Jul;302(1):126-146. 10.1111/imr.12971. Epub May 13. 33987902. Acknowledgements: NIL. Disclosure Interests None Declared.